Literature DB >> 26474427

Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases.

Michelle Kang Kim1, Fei Ye, Daguang Wang, Miao Cui, Stephen C Ward, Richard R P Warner, Sasan Roayaie, Michail Shafir, Myron Schwartz, David Zhang, Steven Itzkowitz.   

Abstract

OBJECTIVE: Small intestinal neuroendocrine tumors (SI-NETs) are often detected after they have become metastatic. Using a novel protein array, we identified pathways important in SI-NET metastasis development in surgically resected patients.
METHODS: Paired primary tumors and liver metastases from 25 patients undergoing surgical resection for metastatic SI-NETs were harvested. Extracted proteins were separated by sodium dodecyl sulfate gel and multiplex immunoblots were performed with 136 antibodies. Significant Analysis of Microarray was used to select for differentially expressed proteins. A tissue microarray was constructed from 27 archived specimens and stained by immunohistochemistry.
RESULTS: Comparing primary SI-NETs with matched normal small-bowel mucosa, 9 proteins were upregulated and cyclin E was downregulated. The SI-NET liver metastases demonstrated upregulation of P-ERK and p27 but downregulation of CDK2 and CDC25B. When comparing primary SI-NET with their paired liver metastases, cyclin E demonstrated a significant upregulation in the liver metastasis. Tissue microarray demonstrated higher p38 expression and lower Cdc 25b expression in SI-NETs versus liver metastases and confirmed higher expression of p27 in liver metastases versus normal liver.
CONCLUSIONS: Few studies have compared protein expression in paired primary and metastatic SI-NETs. Our findings reveal changes in a limited number of proteins, suggesting that these may be targets for therapy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26474427      PMCID: PMC4783230          DOI: 10.1097/MPA.0000000000000459

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  25 in total

1.  AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors.

Authors:  Christoph R Gloesenkamp; Bianca Nitzsche; Matthias Ocker; Pietro Di Fazio; Karl Quint; Björn Hoffmann; Hans Scherübl; Michael Höpfner
Journal:  Int J Oncol       Date:  2011-11-07       Impact factor: 5.650

Review 2.  ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions.

Authors:  Philippe P Roux; John Blenis
Journal:  Microbiol Mol Biol Rev       Date:  2004-06       Impact factor: 11.056

Review 3.  Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.

Authors:  Michael Höpfner; Detlef Schuppan; Hans Scherübl
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

Review 4.  Biochemical testing for neuroendocrine tumors.

Authors:  Aaron I Vinik; Maria P Silva; Eugene A Woltering; Gene Woltering; Vay Liang W Go; Richard Warner; Martyn Caplin
Journal:  Pancreas       Date:  2009-11       Impact factor: 3.327

5.  Protein signature for non-small cell lung cancer prognosis.

Authors:  Wei Liu; Yong Wu; Libo Wang; Ling Gao; Yingping Wang; Xiaoliang Liu; Kai Zhang; Jena Song; Hongxia Wang; Thomas A Bayer; Laurel Glaser; Yezhou Sun; Weijia Zhang; Michael Cutaia; David Y Zhang; Fei Ye
Journal:  Am J Cancer Res       Date:  2014-05-26       Impact factor: 6.166

Review 6.  The use of chromogranin, synaptophysin and islet amyloid polypeptide as markers for neuroendocrine tumours.

Authors:  M Stridsberg
Journal:  Ups J Med Sci       Date:  1995       Impact factor: 2.384

Review 7.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

8.  The effect of Scutellaria baicalensis on the signaling network in hepatocellular carcinoma cells.

Authors:  Fei Ye; Yufang Che; Elizabeth McMillen; Justin Gorski; Douglas Brodman; Daisy Saw; Bo Jiang; David Y Zhang
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

9.  Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baicalensis.

Authors:  David Y Zhang; Josephine Wu; Fei Ye; Li Xue; Shiquan Jiang; Jizu Yi; Wandi Zhang; Huachen Wei; Max Sung; Wayne Wang; Xiaoping Li
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

10.  Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours.

Authors:  G B Turner; B T Johnston; D R McCance; A McGinty; R G P Watson; C C Patterson; J E S Ardill
Journal:  Gut       Date:  2006-03-23       Impact factor: 23.059

View more
  2 in total

1.  Genetic heterogeneity of primary lesion and metastasis in small intestine neuroendocrine tumors.

Authors:  Dirk Walter; Patrick N Harter; Florian Battke; Ria Winkelmann; Markus Schneider; Katharina Holzer; Christine Koch; Jörg Bojunga; Stefan Zeuzem; Martin Leo Hansmann; Jan Peveling-Oberhag; Oliver Waidmann
Journal:  Sci Rep       Date:  2018-02-28       Impact factor: 4.379

Review 2.  High-throughput proteomics: a methodological mini-review.

Authors:  Miao Cui; Chao Cheng; Lanjing Zhang
Journal:  Lab Invest       Date:  2022-08-03       Impact factor: 5.502

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.